For Bayer, an FDA Approval Arrives Just as a US Trade Storm Gathers
19.06.2026 - 19:05:25 | boerse-global.de
The contrast could hardly be starker. On Friday, Bayer won US regulatory clearance for its new MRI contrast agent AMBELVIST, sending the stock nearly 5% higher on the week. Yet within hours of that positive news, the US Trade Representative launched an investigation into German drug pricing that could ultimately slap tariffs on the very pharmaceutical exports Bayer is counting on.
The green light from the Food and Drug Administration covers AMBELVIST (Gadoquatrane) for contrast-enhanced MRI in adults and children, including newborns. The agent detects lesions in the central nervous system and other body areas. Its key selling point is a dose of just 0.01 mmol/kg — 60% less gadolinium than standard agents at 0.1 mmol/kg and 20% less than the nearest competitor Gadopiclenol. That makes AMBELVIST the lowest-dose macrocyclic gadolinium contrast agent ever approved in the US. The FDA’s decision rests on two randomised Phase III trials: QUANTI CNS for central nervous system pathologies and QUANTI OBR for areas outside the CNS. Japan already cleared the drug in March 2026, while applications remain pending in Europe and China.
But any celebration in Leverkusen is tempered by a simultaneous threat from Washington. Trade Representative Jamieson Greer on Friday launched a formal investigation, alleging that Germany maintains artificially low drug prices while US patients shoulder a disproportionate share of research costs. If the probe finds evidence of unfair practices, the administration could impose punitive tariffs on German pharmaceuticals. Months of talks between Washington and Berlin have failed to produce a deal; the US concluded a similar pact with the UK in April.
Should investors sell immediately? Or is it worth buying Bayer?
Across the Atlantic, Brussels handed Bayer a quieter but meaningful win. The European Parliament on Thursday voted to loosen rules on genetically modified crops, creating a new category for gene-edited plants. These will no longer require special labels or lengthy approval processes, provided the genetic changes are considered minor. Crucially, patents on such modified seeds remain explicitly permitted. The new rules take effect in mid-2028 and give Bayer’s Crop Science division a clear competitive edge in the EU.
The legal overhang from glyphosate, however, refuses to fade. Bayer is braced for roughly €5 billion in litigation outflows this year, pushing free cash flow into negative territory as deep as minus €2.5 billion. The next major courtroom date is 9 July 2026 in St. Louis, where a judge will review the multi-billion-dollar settlement that was sent back from a Missouri appeals court. That hearing will determine whether the company can finally cap its Roundup exposure or faces a fresh wave of trials.
Analyst reaction to the FDA news has been measured. Berenberg lifted its price target from €40.00 to €40.50, keeping a “Hold” rating; analyst Sebastian Bray cited improved pharma profitability and favourable currency effects. UBS remains more optimistic at €52.00 with a “Buy” recommendation, viewing the US approval as a tailwind for the pharmaceuticals division. Jefferies also rates the stock a “Hold” with a €40.00 target.
After the FDA announcement, Bayer shares climbed to €37.84, a gain of around 2% on the day. That puts the stock just above its 50-day moving average of €37.80 — the first time it has held that level in months after sustained pressure. It also trades comfortably above the 200-day average of €36.22. Even so, the shares are still 24% below the 52-week high of €49.93. The FDA decision provides a concrete argument for the pharma pipeline, but with a trade investigation looming and a critical glyphosate hearing in July, the relief may prove short-lived.
Ad
Bayer Stock: New Analysis - 19 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
